Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. News archives / 新聞典藏
  3. 焦點新聞
  4. 8/8 糖尿病藥物「二甲雙胍」有望降低失智風險 北醫大研究登上國際期刊
 
  • Details
Options

8/8 糖尿病藥物「二甲雙胍」有望降低失智風險 北醫大研究登上國際期刊

Type
newspaper
Date Issued
2025-08-08
Author(s)
秘書處/SL
Subjects
焦點新聞
Abstract
近年來人口老化與失智症議題備受關注,臺北醫學大學最新研究發現,常用於糖尿病治療用藥「二甲雙胍(Metformin)」,不僅有助於血糖控制,對於肥胖病人而言,長期使用更可望顯著降低罹患失智症與整體死亡率的風險。這項突破性發現已發表於國際期刊《Diabetes, Obesity and Metabolism》,並獲美國醫學新聞網站 News Medical 報導。
URI
https://203.71.86.71/handle/123456789/43353
File(s)
No Thumbnail Available
Name

attachment.pdf

Size

318.26 KB

Format

Adobe PDF

Checksum

(MD5):78543bce3c2e48e5fea5b07ef50df429

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback